iron deficiencyanemia and kidney disease product pipelinetriferic triferic triferic clinical development progress dialysis products triferic calcitriol vitamin d injectionhemodialysis concentratescitrapure dri sate safety data sheetsancillary productsrenal pure rockwell customer servicerockwell transportation and delivery media centerlinks to additional resourcespublications dialysis productsrockwell medical is a fully integrated biopharmaceutical company targeting end stage renal disease esrd and chronic kidney disease ckd with innovative products and services for the treatment of iron deficiency anemia secondary hyperparathyroidism and hemodialysis throughout the u.s. and abroad . learn more bio pharma development programthe company s lead bio pharmaceutical iron drug triferic was commercially launched in the u.s. september 2015 and is designed to prevent and treat iron deficiency anemia in end stage renal disease patients . as part of the our long term growth strategy the company is establishing global partnerships and licensing opportunities for world wide distribution and sale of all it s therapies . learn more kidney diseasediseases of the kidney are a major health concern in the united states affecting more than 30 million americans and causing more than 100 000 deaths annually . learn more investor center rockwell medical s common shares are traded on nasdaq under the symbol rmti . more about usrockwell is a fully integrated biopharmaceutical company targeting end stage renal disease esrd and chronic kidney disease ckd with innovative products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis . as an established manufacturer and leader in delivering high quality hemodialysis concentrates to dialysis providers and distributors in the u.s. and abroad rockwell provides products used to maintain human life removing toxins and replacing critical nutrients in the dialysis patient s bloodstream . more latest news 10 4 16 rockwell medical announces triferic human intravenous iv pharmacokinetic study published in journal of clinical pharmacology publication highlights human dose response lack of non transferrin bound iron and labile plasma iron 9 22 16 rockwell medical preparing for calcitriol commercial launch8 16 16 rockwell medical enters into exclusive license agreement with aram medical to commercialize triferic in saudi arabia egypt and middle east territories territory covers 375 000 ckd hd patients ; rockwell receives upfront licensing fee high double digit royalty and annual contractual minimum product purchases 8 8 16 rockwell medical reports second quarter resultssee all the news visit contact us careers sitemap privacy policy terms of use